<DOC>
	<DOCNO>NCT00915460</DOCNO>
	<brief_summary>To collect data serious adverse event occur extend treatment Avonex subject high risk develop multiple sclerosis ( MS ) subject secondary progressive MS .</brief_summary>
	<brief_title>Open-Label Safety Extension Study Avonex</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Must complete ( define ) one follow Biogen AVONEXÂ® clinical study meet criterion indicate . Subjects enrol study C95812 C97830 must complete respective study within 12 month prior enrollment C98838 . Subjects enrol study C96823 must complete study within 24 month prior enrollment C98838 . diagnose disease account neurologic symptom . History significant cardiac , hepatic , pulmonary , renal disease ; immune deficiency ; medical condition would preclude therapy interferon beta . History severe allergic anaphylactic reaction history hypersensitivity human albumin . History seizure within 3 month prior enrollment . Abnormal laboratory result screen visit : History suicidal ideation episode severe depression within 3 month prior enrollment study . Other inclusion exclusion criterion apply per Biogen Idec Protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Avonex</keyword>
	<keyword>Interferon beta-1a</keyword>
	<keyword>patient high risk develop multiple sclerosis</keyword>
</DOC>